Supernus Pharmaceuticals (SUPN) AI Stock Analysis

• Market Cap: $1.86B
• Dividend Yield: N/A
• Average Volume (3M): 663.09K
• Price to Earnings (P/E): 30.0
• Beta (1Y): 0.60
• Revenue Growth: 11.82%
• EPS Growth: N/A
• Country: US
• Employees: 674
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.44
• Shares Outstanding: 55,989,624
• 10 Day Avg. Volume: 681,920
• 30 Day Avg. Volume: 663,089
• PEG Ratio: -1.86
• Price to Book (P/B): 1.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.06
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 0.66
• Enterprise Value/Gross Profit: 3.25
• Enterprise Value/Ebitda: 2.78
• 1Y Price Target: $39.00
• Price Target Upside: 17.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 72 Outperform
• Price Target: $36.00 ▲(8.70%Upside)

Supernus Pharmaceuticals demonstrates strong financial stability and strategic growth through acquisitions. However, valuation concerns and technical indicators suggest caution. The company's growth in core products and strategic acquisitions are promising, but offset by challenges with legacy product declines and patent issues.

Positive Factors

Product Launch and Market Opportunity

The FDA has approved Onapgo (SC apomorphine pump) to treat OFF episodes in Parkinson's disease, offering a significant market opportunity.

Sales Performance

Qelbree solidly exceeded expectations, with $74.4MM in Q4 sales, reflecting solid demand.

Stock Price Target

The price target for Supernus Pharmaceuticals stock has been increased from $44.00 to $45.00.

Negative Factors

Clinical Trial Challenges

No subgroup profiles or specific data trends stood out in the SPN-820 trial, indicating potential challenges in differentiating treatment effects.

Clinical Trial Results

Disappointing Phase 2b data from SPN-820 in treatment-resistant patients led to a downgrade of the stock rating.

Supernus Pharmaceuticals Business Overview & Revenue Model

Company Description

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

How the Company Makes Money

Supernus Pharmaceuticals primarily generates revenue through the sales of its pharmaceutical products. The company's key revenue streams include product sales from its portfolio of CNS-related therapies, which are marketed directly to healthcare providers and sold through various distribution channels. Supernus also engages in strategic partnerships and collaborations with other pharmaceutical companies to expand its market reach and enhance its product offerings. Additionally, the company may receive milestone payments and royalties from licensing agreements related to its proprietary drug formulations and technologies. These combined efforts contribute to Supernus's earnings and financial growth.

Supernus Pharmaceuticals Financial Statement Overview

Summary

Supernus Pharmaceuticals demonstrates a strong financial position, characterized by robust margins and a solid equity base. The company maintains low leverage, reducing financial risk while ensuring ample liquidity. Despite moderate revenue growth, stable cash flows and efficient cost management underscore its operational resilience. Opportunities exist to enhance shareholder returns through improved net income generation.

Income Statement

Supernus Pharmaceuticals demonstrated a solid gross profit margin of 79.5% in the TTM, indicating strong cost management. The net profit margin of 9.3% suggests reasonable profitability, despite a slight decline from the previous year. Revenue growth is relatively modest, reflecting stable but limited expansion opportunities. EBITDA margin is healthy at 25.0%, supporting operational efficiency.

Balance Sheet

The company exhibits a robust equity position with an equity ratio of 76.5% in the TTM, highlighting financial stability. The debt-to-equity ratio is low at 0.03, indicating minimal leverage and reduced financial risk. Return on equity is moderate at 6.0%, suggesting room for improvement in generating returns for shareholders.

Cash Flow

Operating cash flow remains strong with an operating cash flow to net income ratio of 2.65, indicating efficient cash generation relative to income. Free cash flow growth has been stable, supporting potential reinvestment or shareholder returns. However, the free cash flow to net income ratio of 2.64 suggests a balanced but not overly aggressive cash deployment strategy.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	668.00M	661.82M	607.52M	667.24M	579.77M	520.40M
Gross Profit	531.00M	583.91M	523.74M	580.02M	504.71M	467.94M
EBITDA	166.97M	178.28M	90.04M	153.44M	129.19M	212.40M
Net Income	61.91M	73.86M	1.32M	60.71M	53.42M	126.95M
Balance Sheet
Total Assets	1.35B	1.37B	1.28B	1.70B	1.69B	1.50B
Cash, Cash Equivalents and Short-Term Investments	463.59M	453.61M	254.87M	461.33M	339.68M	422.53M
Total Debt	32.30M	34.27M	41.53M	437.97M	420.55M	390.33M
Total Liabilities	316.58M	332.34M	356.16M	816.30M	873.30M	759.24M
Stockholders Equity	1.03B	1.04B	921.52M	886.20M	815.85M	744.86M
Cash Flow
Free Cash Flow	163.34M	171.23M	110.53M	116.41M	125.08M	134.95M
Operating Cash Flow	164.15M	171.95M	111.08M	116.83M	127.13M	138.40M
Investing Cash Flow	-100.93M	-189.87M	268.73M	-216.66M	-81.91M	-34.70M
Financing Cash Flow	-10.78M	12.19M	-397.88M	-10.48M	-130.42M	3.56M

Supernus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 33.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SUPN, the sentiment is Positive. The current price of 33.12 is above the 20-day moving average (MA) of 32.10, above the 50-day MA of 32.27, and below the 200-day MA of 34.05, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 59.91 is Neutral, neither overbought nor oversold. The STOCH value of 79.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SUPN.

Supernus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIP	74 Outperform	$1.41B	―	-5.19%	―	30.26%	-173.36%
SUPN	72 Outperform	$1.86B	29.99	6.32%	―	11.82%	―
AMPH	69 Neutral	$1.02B	7.86	19.90%	―	8.05%	-8.46%
AMRX	63 Neutral	$2.61B	―	106.97%	―	13.42%	92.50%
DVAX	52 Neutral	$1.31B	64.45	-10.45%	―	24.76%	-783.38%
Sector *	52 Neutral	$7.51B	0.24	-62.67%	2.30%	16.09%	0.95%
EVO	49 Neutral	$1.49B	―	-20.41%	―	0.45%	-125.61%

Supernus Pharmaceuticals Corporate Events

Supernus Pharmaceuticals Holds Annual Stockholders Meeting

On June 16, 2025, Supernus Pharmaceuticals held its annual stockholders meeting, where key decisions were made regarding the election of directors, executive compensation, and the appointment of KPMG LLP as the independent public accounting firm for 2025. These decisions are expected to influence the company’s governance and financial oversight, impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.

Supernus Pharmaceuticals to Acquire Sage Therapeutics

On June 13, 2025, Supernus Pharmaceuticals announced a definitive agreement to acquire Sage Therapeutics through a tender offer valued at approximately $795 million. This acquisition is expected to enhance Supernus’ neuropsychiatry product portfolio with the addition of ZURZUVAE, an FDA-approved treatment for postpartum depression, and is anticipated to be significantly accretive by 2026, with potential cost synergies of up to $200 million annually.

The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.

Supernus Pharmaceuticals Faces Patent Challenges for Qelbree

On May 22 and 23, 2025, Supernus Pharmaceuticals received Paragraph IV Notice Letters indicating that third parties filed Abbreviated New Drug Applications (ANDAs) for viloxazine hydrochloride capsules, challenging the patents of their product Qelbree. Supernus plans to enforce its intellectual property rights, which are protected by six U.S. patents expiring between 2029 and 2035, potentially impacting its market position and stakeholder interests.

The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.